Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST

-- Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) -- -- Company prioritizing THE-349, a...

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Philadelphia ,Pennsylvania ,Tim Clackson ,Josh Rappaport ,Drug Administration ,Prnewswire Theseus Pharmaceuticals Inc ,Theseus Pharmaceuticals Inc ,Exchange Commission ,Theseus Pharmaceuticals ,Nasdaq ,Chief Executive Officer ,Investigational New Drug Application ,Theseu Form ,Quarterly Reports ,